Article
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
The Lancet. Oncology - 1 Feb 2010
Mitsudomi Tetsuya, Morita Satoshi, Yatabe Yasushi, Negoro Shunichi, Okamoto Isamu, Tsurutani Junji, Seto Takashi, Satouchi Miyako, Tada Hirohito, Hirashima Tomonori, Asami Kazuhiro, Katakami Nobuyuki, Takada Minoru, Yoshioka Hiroshige, Shibata Kazuhiko, Kudoh Shinzoh, Shimizu Eiji, Saito Hiroshi, Toyooka Shinichi, Nakagawa Kazuhiko, Fukuoka Masahiro
Abstract excerpt
BACKGROUND: Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain. METHODS: We did an open label, phase 3 study (WJTOG3405) with recruitment between...
Topics
- Aged
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Docetaxel
- ErbB Receptors
- Female
- Gefitinib